Hi Reader,

Jake Weber here. At the end of June, two biotech stocks, Vaxart (VXRT) and Inovio (INO), went up 219% and 108%, respectively... in ONE week. Guess what those two stocks had in common: Both of them delivered good news on their COVID-19 vaccine candidates.

I know you’re probably tired of hearing about coronavirus at this point. So am I.

That doesn’t change the fact, though, that biotech companies working on promising therapies or drugs for anything COVID-19 related are absolutely crushing it.

In our in-depth briefing on our top two Biotech Millionaire portfolio stocks, my co-editor Chris Wood and I told you about a small biotech company that treats not one but two dangerous diseases with its spectacular flagship technology.

One of them is the leading cause of death in coronavirus patients.

Like the two stocks I mentioned above, this company recently received a major COVID boost. Between March 16 and April 1, its share price leaped by 237.3%, from $1.18 per share to $3.98. And there is MUCH more to come.

Right now, the stock has settled down a bit from its heights, which makes it a great time to get in... and become a charter member of our premium alert service, Biotech Millionaire.

But time is of the essence—BEFORE these two stocks shoot up (one of them is already on the rise) and BEFORE our deep-discount offer to join us expires in a few days.

If you haven’t watched our presentation yet, I urge you to do so now. Or if you prefer, you can read through the material here.

In it, you’ll discover:

• Two “Hawking Factor” companies with treatments so revolutionary, they could completely transform the lives of millions of patients
• ALL the details—including name, ticker symbol, target price, and Buy instructions—on a company that tackles and may even REVERSE the disease genius scientist Stephen Hawking suffered from... with a potential upside of up to 1,000%
• The company that fights two of the worst killers of our time... upside potential: 1,270% within the next 12–18 months
• How to get all you need to know to confidently invest in these companies... AND receive discounts and free research valued at $2,394

Just imagine raking in 108%, 219%, 237.3%, or more... in one week.

You don’t want to buy Vaxart and Inovio now, after their big runup. But our second “Hawking Factor” company hasn’t even really gotten started yet.

There’s still a lot of room for growth... up to 1,270% within the next 12–18 months.

Get ALL the details on this and our other “Hawking Factor” stock here. We’re giving away all you need to know to buy into the first stock in our presentation, so don’t miss it.

Right now is the optimal time to invest in this stock. It has gained a bit of momentum already, which shows that investors are getting excited about the therapy... but it’s not running away from us yet, so there’s still time to get in BEFORE the big money is made.

But you have to move fast—this is a time-sensitive opportunity.

You MUST act before the end of July 16 to receive our huge package of discounts and free research worth $2,394.

Watch the presentation now.

Best,

Jake Weber
Senior Healthcare and Biotech Analyst
Mauldin Economics

P.S. If you have already watched our detailed briefing, “Earn 1,000% with the Hawking Factor,” and just want to cut to the chase, click here to go straight to our deep-discount offer.